[News] ESMO Gastrointestinal Cancers Congress 2024

Elisa Fontana (Sarah Cannon Research Institute UK, London, UK) presented results from the phase 1 MINOTAUR trial of the first-in-class PKMYT1 inhibitor lunresertib in combination with standard FOLFIRI for advanced gastrointestinal cancers. Lunresertib targets CCNE1 amplifications or FBXW7 mutations, which occur in around 20% of gastrointestinal cancers and confer a poor prognosis. 38 patients with advanced gastrointestinal cancers positive for these genetic alterations received lunresertib once daily (continuously) or intermittently plus FOLFIRI every 2 weeks.